Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 1 , Pages 15-31 , March 2007

Tumour biology and histopathology of neuroendocrine tumours

References 

  1. Klöppel G. Neuroendokrinen Tumoren des Gastrointestinaltrakts. Der Pathologe. 2003;24:287–296
  2. Klöppel G. Tumoren des endokrinen Pankreas. Der Pathologe. 2003;24:265–271
  3. Lloyd RV. Practical markers used in the diagnosis of neuroendocrine tumors. Endocrine Pathology. 2003;14:293–301
  4. Erickson LA, Papouchado B, Dimashkieh H, et al. Cdx2 as a marker for neuroendocrine tumors of unknown primary sites. Endocrine Pathology. 2004;15:247–252
  5. La Rosa S, Rigoli E, Uccella S, et al. CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumors. Virchows Archiv. 2004;445:248–254
  6. Cai YC, Banner B, Glickman J, Odze RD. Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors. Human Pathology. 2001;32:1087–1093
  7. Sturm N, Rossi G, Lantuejoul S, et al. Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Human Pathology. 2002;33:175–182
  8. Volante M, Bozzalla-Cassione F, Papotti M. Somatostatin receptors and their interest in diagnostic pathology. Endocrine Pathology. 2004;15:275–292
  9. Reubi JC, Häcki WH, Lamberts SW. Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors. The Journal of Clinical Endocrinology and Metabolism. 1987;65:1127–1134
  10. Lamberts SW, Hofland LJ, van Koetsveld PM, et al. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy [see comments]. The Journal of Clinical Endocrinology and Metabolism. 1990;71:566–574
  11. Kulaksiz H, Eissele R, Rössler D, et al. Identification of somatostatin receptor subtypes 1, 2A, 3 and 5 in neuroendocrine tumours with subtype specific antibodies. Gut. 2002;50:52–60
  12. Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Archiv. 2002;440:461–475
  13. Volante M, Rindi G, Papotti M. The grey zone between pure (neuro)endocrine and non-(neuro)endocrine tumors: a comment on concepts and classification of mixed exocrine-endocrine neoplasms. Virchows Archiv. 2006;449:499–506
  14. Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors. The WHO classification. Annals of the New York Academy of Sciences. 2004;1014:13–27
  15. Plöckinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology. 2004;80:394–424
  16. Rindi G, Klöppel G, Ahlman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv. 2006;449:395–401
  17. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet. 1963;I:238–239
  18. Riddle PJ, Font RL, Zimmerman LE. Carcinoid tumors of the eye and orbit: a clinicopathologic study of 15 cases, with histochemical and electron microscopic observations. Human Pathology. 1982;13:459–469
  19. Mills SE. Neuroendocrine tumors of the head and neck: a selected review with emphasis on terminology. Endocrine Pathology. 1996;7:329–343
  20. Ferlito A, Barnes L, Rinaldo A, et al. A review of neuroendocrine neoplasms of the larynx: update on diagnosis and treatment. The Journal of Laryngology and Otology. 1998;112:827–834
  21. Wick MR, Rosai J. Neuroendocrine neoplasms of the thymus. Pathology, Research and Practice. 1988;183:188–199
  22. Moran CA, Suster S. Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases. American Journal of Clinical Pathology. 2000;114:100–110
  23. Bordi C, Azzoni C, D'Adda T, et al. Neuroendokrine Tumoren des Magens. Der Pathologe. 1997;18:313–321
  24. Klöppel G, Clemens A. The biological relevance of gastric neuroendocrine tumors. The Yale Journal of Biology and Medicine. 1996;69:69–74
  25. Rindi G, Luinetti O, Cornaggia M, et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology. 1993;104:994–1006
  26. Eissele R, Anlauf M, Schäfer MKH, et al. Expression of vesicular monoamine transporters in endocrine hyperplasia and endocrine tumors of the oxyntic stomach. Digestion. 1999;60:428–439
  27. Rindi G, Paolotti D, Fiocca R, et al. Vesicular monoamine transporter 2 as a marker of gastric enterochromaffin-like cell tumors. Virchows Archiv. 2000;436:217–223
  28. Bordi C, D'Adda T, Azzoni C, et al. Gastrointestinal endocrine tumors: recent developments. Endocrine Pathology. 1998;9:99–115
  29. Rappel S, Altendorf-Hofmann A, Stolte M. Prognosis of gastric carcinoid tumours. Digestion. 1995;56:455–462
  30. Capella C, Heitz PU, Höfler H, et al. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Archiv. 1995;425:547–560
  31. Klöppel G, Heitz PU, Capella C, Solcia E. Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions. World Journal of Surgery. 1996;20:132–141
  32. Pipeleers-Marichal M, Somers G, Willems G, et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger–Ellison syndrome. The New England Journal of Medicine. 1990;322:723–727
  33. Pipeleers-Marichal M, Donow C, Heitz PU, Klöppel G. Pathologic aspects of gastrinomas in patients with Zollinger–Ellison syndrome with and without multiple endocrine neoplasia type I. World Journal of Surgery. 1993;17:481–488
  34. Donow C, Pipeleers-Marichal M, Schröder S, et al. Surgical pathology of gastrinoma. Site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy. Cancer. 1991;68:1329–1334
  35. Weber HC, Venzon DJ, Lin JT, et al. Determinants of metastatic rate and survival in patients with Zollinger–Ellison syndrome: a prospective long-term study. Gastroenterology. 1995;108:1637–1649
  36. Grabowski P, Schönfelder J, Ahnert-Hilger G, et al. Expression of neuroendocrine markers: a signature of human undifferentiated carcinoma of the colon and rectum. Virchows Archiv. 2002;441:256–263
  37. Klöppel G, In't Veld PA, Komminoth P, Heitz PU. The endocrine pancreas. In:  Kovacs K,  Asa SL editor. Functional Endocrine Pathology. 2nd ed. Boston: Blackwell; 1998;p. 415–487
  38. Solcia E, Klöppel G, Sobin LH, (In collaboration with 9 pathologists from 4 countries) . In: Histological typing of endocrine tumours. WHO international histological classification of tumours. 2nd ed. Berlin: Springer; 2000;
  39. Heymann MF, Joubert M, Nemeth J, et al. Prognostic and immunohistochemical validation of the Capella classification of pancreatic neuroendocrine tumours: an analysis of 82 sporadic cases. Histopathology. 2000;36:421–432
  40. La Rosa S, Sessa F, Capella C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Archiv. 1996;429:323–333
  41. Roth J, Klöppel G, Madsen OD, et al. Distribution patterns of proinsulin and insulin in human insulinomas: an immunohistochemical analysis in 76 tumors. Virchows Archiv. B: Cell Pathology. 1992;63:51–61
  42. Creutzfeldt W, Arnold R, Creutzfeldt C, et al. Biochemical and morphological investigations of 30 human insulinomas. Correlation between the tumour content of insulin and proinsulin-like components and the histological and ultrastructural appearance. Diabetologia. 1973;9:217–231
  43. Goebel SU, Heppner C, Burns AL, et al. Genotype/phenotype correlation of multiple endocrine neoplasia type 1 gene mutations in sporadic gastrinomas. The Journal of Clinical Endocrinology and Metabolism. 2000;85:116–123
  44. Barghorn A, Komminoth P, Bachmann D, et al. Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression. Journal of Pathology. 2001;194:451–458
  45. Speel EJ, Scheidweiler AF, Zhao J, et al. Genetic evidence for early divergence of small functioning and nonfunctioning endocrine pancreatic tumors: gain of 9Q34 is an early event in insulinomas. Cancer Research. 2001;61:5186–5192
  46. D'Adda T, Pizzi S, Azzoni C, et al. Different patterns of 11q allelic losses in digestive endocrine tumors. Human Pathology. 2002;33:322–329
  47. Tönnies H, Toliat MR, Ramel C, et al. Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation. Gut. 2001;48:536–541
  48. Kytölä S, Höög A, Nord B, et al. Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids. American Journal of Pathology. 2001;158:1803–1808

PII: S1521-690X(07)00005-X

doi: 10.1016/j.beem.2007.01.004

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 1 , Pages 15-31 , March 2007

Article Tools

* Image Usage & Resolution